The Spinal Cord Injury Therapeutics Market is estimated to be valued at US$ 7.4 billion in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Spinal cord injury therapeutics are medicinal products aimed at treating various injuries to the spinal cord. These include pharmacological therapies, reconstructive surgeries and rehabilitation therapies. Spinal cord injuries can occur due to trauma, tumors or degenerative disorders. The therapeutics help in the repair and regeneration of damaged nerve tissues, reduce inflammation and manage pain. Their adoption allows for faster recovery and improved quality of life for patients.
Market key trends:
One of the major trends driving growth in this market is the increasing research and development activities for developing advanced therapies. Over the past few years, substantial investments have been made towards developing cell-based and gene-based therapies for spinal cord injuries. Companies are collaborating to conduct clinical trials on stem cell therapies, gene therapies and neural interfaces. For instance, Swiss biotech company SpinalCyte is collaborating with Teva Pharmaceuticals to evaluate a stem cell-based therapy for chronic cervical spinal cord injuries. SpinalCyte’s therapy uses stem cells derived from adipose tissue to reduce inflammation and promote nerve regeneration at the injury site. Such emerging therapies hold promise to significantly improve functional recovery in patients. Their successful development and commercialization will further augment the growth of this market during the forecast period.
Porter’s Analysis
Threat of new entrants: Low costs of production for new entrants given the specialized nature of the market. However, the necessity for strong R&D capabilities and regulations pose a barrier.
Bargaining power of buyers: Buyers have significant bargaining power given the availability of alternative treatment options and ability to negotiate on price. Their bargaining power is expected to increase with rising demand.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to limited availability of raw materials and dependence of buyers on crucial inputs. However, the presence of substitutes keeps their power in check.
Threat of new substitutes: Threat of new substitutes remains high with ongoing innovation and research leading to newer treatment alternatives.
Competitive rivalry: Intense due to numerous established players and large revenue potential.
SWOT Analysis
Strengths: Strong R&D abilities, diversified product portfolio, global presence for major players.
Weaknesses: High costs associated with development and clinical trials, stringent regulations delaying market entry.
Opportunities: Rising incidence rates, growing geriatric population susceptible to conditions, collaborations for new product development.
Threats: Patent cliffs on blockbuster drugs, pricing pressures, uncertainties around reimbursements.
Key Takeaways
The global Spinal Cord Injury Therapeutics Market Trend is expected to witness high growth, exhibiting CAGR of 5.4% over the forecast period, due to increasing incidence of spinal cord injuries from road accidents and trauma cases. North America currently holds the largest share due to high healthcare spending and presence of major market players. However, Asia Pacific is expected to grow at the fastest pace with growth in healthcare infrastructure and raising awareness.
Key players operating in the Spinal Cord Injury Therapeutics market are Teva Pharmaceutical Industries Ltd., AbbVie Inc, Pfizer Inc., Reddy's Laboratories Ltd, Zydus Cadila, ReNetX Bio, Inc, InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc, Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc, RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc, ScieGen Pharmaceuticals, Inc, MSN Laboratories Private Limited, and Lannett Co Inc. The major players are focusing on newer product approvals and strategic collaborations for sustained market leadership.
Read more @ https://www.newsstatix.com/emerging-opportunities-for-cell-therapy-in-spinal-cord-injury-demand/